Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(1 site)
United States
Brigham and Women's Hospital / Dana Farber Cancer Institute, Boston, Massachusetts